Humana Inc. $HUM Shares Bought by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG grew its holdings in Humana Inc. (NYSE:HUM) by 41.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,773 shares of the insurance provider’s stock after purchasing an additional 1,389 shares during the period. J. Safra Sarasin Holding AG’s holdings in Humana were worth $827,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Sound View Wealth Advisors Group LLC increased its position in shares of Humana by 3.5% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,060 shares of the insurance provider’s stock worth $272,000 after purchasing an additional 36 shares during the last quarter. CoreCap Advisors LLC raised its holdings in Humana by 54.4% in the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after buying an additional 37 shares during the period. Columbus Macro LLC lifted its position in Humana by 5.5% in the fourth quarter. Columbus Macro LLC now owns 821 shares of the insurance provider’s stock valued at $210,000 after buying an additional 43 shares during the last quarter. Fiduciary Alliance LLC lifted its position in Humana by 0.9% in the first quarter. Fiduciary Alliance LLC now owns 5,628 shares of the insurance provider’s stock valued at $976,000 after buying an additional 49 shares during the last quarter. Finally, Sanctuary Advisors LLC boosted its stake in Humana by 1.6% during the fourth quarter. Sanctuary Advisors LLC now owns 3,389 shares of the insurance provider’s stock worth $868,000 after buying an additional 52 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of HUM opened at $406.70 on Wednesday. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $415.00. The firm’s 50 day moving average price is $345.52 and its 200 day moving average price is $257.26. The company has a market cap of $48.83 billion, a P/E ratio of 43.50, a PEG ratio of 2.31 and a beta of 0.71. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.66.

Humana (NYSE:HUM) last released its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. Humana had a net margin of 0.82% and a return on equity of 10.45%. The company had revenue of $39.65 billion for the quarter, compared to analyst estimates of $39.37 billion. During the same period in the prior year, the business earned $11.58 EPS. The firm’s quarterly revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS. On average, research analysts forecast that Humana Inc. will post 9.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. TD Cowen lifted their price target on shares of Humana from $211.00 to $350.00 and gave the company a “hold” rating in a research report on Tuesday. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $425.00 price objective on shares of Humana in a research report on Wednesday, June 3rd. Weiss Ratings upgraded shares of Humana from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 29th. Truist Financial boosted their target price on Humana from $320.00 to $415.00 and gave the company a “hold” rating in a research report on Tuesday. Finally, Cantor Fitzgerald upped their price target on Humana from $264.00 to $300.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, sixteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $325.87.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.